Compare Crispr Therapeutics AG (CRSP) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs QUALCOMM, Inc. — how do they compare? Crispr Therapeutics AG trades at $51.36 (market cap $4.97B), while QUALCOMM, Inc. trades at $178.04 (market cap $187.72B). The key difference: QUALCOMM, Inc. is far larger — about 37.8× Crispr Therapeutics AG's market cap, and QUALCOMM, Inc. pays a 2.07% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | QCOM | |
|---|---|---|
Market Cap | $4.97B | $187.72B |
Sector | Health | Technology |
52-Week High | $76.78 | $251.10 |
52-Week Low | $44.34 | $124.07 |
Enterprise Value | $3.32B | $193.19B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Qualcomm (QCOM) trades at $183.98, down 2.74% on the day, amid a bearish technical signal. The company maintains strong profitability with 54.8% gross margins and 22.31% net income margin, though revenue growth has been modest. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.56 estimate. Analyst consensus remains positive with a $222.53 price target, representing 21% upside potential from current levels.
Qualcomm faces near-term headwinds from smartphone market softness but is successfully diversifying into automotive and AI data centers. The stock offers value at 19.15x P/E with strong cash flow generation, though competition from Nvidia in PC chips presents execution risk. With 42.65% of analysts rating it Buy and solid balance sheet fundamentals, QCOM presents a compelling long-term opportunity despite technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
